JP2014518546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518546A5 JP2014518546A5 JP2013557882A JP2013557882A JP2014518546A5 JP 2014518546 A5 JP2014518546 A5 JP 2014518546A5 JP 2013557882 A JP2013557882 A JP 2013557882A JP 2013557882 A JP2013557882 A JP 2013557882A JP 2014518546 A5 JP2014518546 A5 JP 2014518546A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- active agent
- arginine
- lysine
- side chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 claims 45
- 239000004475 Arginine Substances 0.000 claims 28
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 28
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 28
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 28
- 239000004472 Lysine Substances 0.000 claims 28
- 150000001413 amino acids Chemical class 0.000 claims 28
- 229960003121 arginine Drugs 0.000 claims 28
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 28
- 235000009697 arginine Nutrition 0.000 claims 28
- 229960003646 lysine Drugs 0.000 claims 28
- 229940024606 amino acid Drugs 0.000 claims 25
- 235000001014 amino acid Nutrition 0.000 claims 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 24
- 229940002612 prodrug Drugs 0.000 claims 21
- 239000000651 prodrug Substances 0.000 claims 21
- 102000004190 Enzymes Human genes 0.000 claims 19
- 108090000790 Enzymes Proteins 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 12
- 239000004471 Glycine Substances 0.000 claims 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 12
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 12
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 12
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 12
- 239000004473 Threonine Substances 0.000 claims 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 12
- 229960003767 alanine Drugs 0.000 claims 12
- 235000004279 alanine Nutrition 0.000 claims 12
- 229960001230 asparagine Drugs 0.000 claims 12
- 235000009582 asparagine Nutrition 0.000 claims 12
- 229960005261 aspartic acid Drugs 0.000 claims 12
- 235000003704 aspartic acid Nutrition 0.000 claims 12
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 12
- 229960002433 cysteine Drugs 0.000 claims 12
- 235000018417 cysteine Nutrition 0.000 claims 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 12
- 229960002989 glutamic acid Drugs 0.000 claims 12
- 235000013922 glutamic acid Nutrition 0.000 claims 12
- 239000004220 glutamic acid Substances 0.000 claims 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 12
- 235000004554 glutamine Nutrition 0.000 claims 12
- 229960002743 glutamine Drugs 0.000 claims 12
- 229960002449 glycine Drugs 0.000 claims 12
- 229960002885 histidine Drugs 0.000 claims 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 12
- 229960000310 isoleucine Drugs 0.000 claims 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 12
- 229960003136 leucine Drugs 0.000 claims 12
- 229930182817 methionine Natural products 0.000 claims 12
- 229960004452 methionine Drugs 0.000 claims 12
- 229960005190 phenylalanine Drugs 0.000 claims 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 12
- 229960002429 proline Drugs 0.000 claims 12
- 229960001153 serine Drugs 0.000 claims 12
- 229960002898 threonine Drugs 0.000 claims 12
- 229960004799 tryptophan Drugs 0.000 claims 12
- 229960004441 tyrosine Drugs 0.000 claims 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 12
- 229960004295 valine Drugs 0.000 claims 12
- 239000004474 valine Substances 0.000 claims 12
- 150000001408 amides Chemical class 0.000 claims 10
- 239000002532 enzyme inhibitor Substances 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 150000002576 ketones Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 10
- 125000003368 amide group Chemical group 0.000 claims 9
- 229940125532 enzyme inhibitor Drugs 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 230000003278 mimic effect Effects 0.000 claims 8
- 230000003647 oxidation Effects 0.000 claims 8
- 238000007254 oxidation reaction Methods 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- -1 amide enol Chemical class 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 125000004442 acylamino group Chemical group 0.000 claims 6
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 150000002085 enols Chemical class 0.000 claims 5
- 150000002466 imines Chemical class 0.000 claims 5
- NMDDZEVVQDPECF-LURJTMIESA-N (2s)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@H](N)C(O)=O NMDDZEVVQDPECF-LURJTMIESA-N 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 4
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 229960003104 ornithine Drugs 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 102000004142 Trypsin Human genes 0.000 claims 3
- 108090000631 Trypsin Proteins 0.000 claims 3
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 3
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 239000012588 trypsin Substances 0.000 claims 3
- 239000002753 trypsin inhibitor Substances 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451019P | 2011-03-09 | 2011-03-09 | |
| US61/451,019 | 2011-03-09 | ||
| US201261583523P | 2012-01-05 | 2012-01-05 | |
| US61/583,523 | 2012-01-05 | ||
| PCT/US2012/028367 WO2012122422A2 (en) | 2011-03-09 | 2012-03-08 | Active agent prodrugs with heterocyclic linkers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518546A JP2014518546A (ja) | 2014-07-31 |
| JP2014518546A5 true JP2014518546A5 (cg-RX-API-DMAC7.html) | 2015-04-30 |
| JP6148182B2 JP6148182B2 (ja) | 2017-06-14 |
Family
ID=46798816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557882A Active JP6148182B2 (ja) | 2011-03-09 | 2012-03-08 | 複素環式リンカーを有する活性薬剤プロドラッグ |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9139612B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2683394B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6148182B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103813800B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012225337B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013022946A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2827662C (cg-RX-API-DMAC7.html) |
| IL (1) | IL228215B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2608305C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012122422A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013503862A (ja) * | 2009-09-08 | 2013-02-04 | シグネーチャー セラピューティクス，インク． | 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物 |
| ES2710617T3 (es) | 2010-04-21 | 2019-04-26 | Signature Therapeutics Inc | Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| ES2584634T3 (es) | 2011-01-11 | 2016-09-28 | Signature Therapeutics, Inc. | Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente |
| EP2683394B1 (en) | 2011-03-09 | 2021-01-06 | Signature Therapeutics, Inc. | Active agent prodrugs with heterocyclic linkers |
| US8685916B2 (en) | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
| WO2013045854A1 (fr) | 2011-09-29 | 2013-04-04 | Ecole Normale Superieure De Lyon | Substrat de peptidase fluorogene |
| AU2014359894B2 (en) | 2013-12-06 | 2020-09-17 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| US11634384B2 (en) | 2014-11-25 | 2023-04-25 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| JP2018534269A (ja) * | 2015-10-01 | 2018-11-22 | エリージウム セラピューティクス， インコーポレイテッド | 過剰摂取および乱用に抵抗性のポリサブユニットオピオイドプロドラッグ |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| US10369292B2 (en) * | 2016-01-15 | 2019-08-06 | W. L. Gore & Associates, Inc. | Syringe plunger assemblies |
| EP3210596A1 (en) * | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical composition |
| EP3231420A1 (en) * | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| EP3210630A1 (en) | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| EP3426674A4 (en) | 2016-03-09 | 2019-08-14 | Blade Therapeutics, Inc. | CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| EP3463576A4 (en) * | 2016-05-25 | 2020-01-15 | Concentric Analgesics, Inc. | MEDICINAL PRODUCTS BASED ON PHENOLIC TRPV1 AGONISTS IN ASSOCIATION WITH LOCAL ANESTHETICS AND VASOCONSTRUCTS TO IMPROVE LOCAL ANESTHESIA |
| SMT202200173T1 (it) | 2016-06-01 | 2022-05-12 | Athira Pharma Inc | Composti |
| EP3481835A4 (en) | 2016-07-05 | 2020-02-26 | Blade Therapeutics, Inc. | CALPAIN MODULATORS AND THEIR THERAPEUTIC USES |
| US10934261B2 (en) | 2016-09-28 | 2021-03-02 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| US11879019B2 (en) | 2016-12-19 | 2024-01-23 | The Regents Of The University Of California | Dual-enzyme responsive peptides |
| EP3554548A4 (en) | 2016-12-19 | 2020-08-19 | The Regents of The University of California | NON-CRUSHABLE PILL FORMULATIONS |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| WO2018170465A1 (en) | 2017-03-17 | 2018-09-20 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| JP7284764B2 (ja) * | 2018-02-23 | 2023-05-31 | ロデス テクノロジーズ | 新規オピオイド化合物及びその使用 |
| WO2020023794A1 (en) | 2018-07-27 | 2020-01-30 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic trpv1 agonists |
| US20220175699A1 (en) | 2019-03-06 | 2022-06-09 | Ensysce Biosciences, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| JP2023505687A (ja) | 2019-12-11 | 2023-02-10 | インスピルナ，インコーポレーテッド | 癌の処置方法 |
| CA3209375A1 (en) * | 2021-03-09 | 2022-09-15 | Ensysce Biosciences Inc. | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| CA3230025A1 (en) | 2021-09-29 | 2023-04-06 | Lynn Kirkpatrick | Enzyme-cleavable methadone prodrugs and methods of use thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
| US5109118A (en) | 1989-07-06 | 1992-04-28 | Yutaka Mizushima | Modified biologically active proteins |
| US5217987A (en) | 1989-10-30 | 1993-06-08 | Berger Stephen P | Dopamine uptake inhibitors in reducing substance abuse and/or craving |
| CA2032420A1 (en) | 1989-12-22 | 1991-06-23 | Akira Okuyama | Guanidinobenzene derivatives |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| KR20000005312A (ko) | 1996-04-10 | 2000-01-25 | 오노 야꾸힝 고교 가부시키가이샤 | 트립타아제 억제제 및 신규 구아니디노 유도체 |
| CA2350531A1 (en) | 1998-11-13 | 2000-05-25 | Smriti Iyengar | Method for treating pain |
| US6586196B1 (en) | 1998-12-15 | 2003-07-01 | Tropix, Inc. | Multiple enzyme assays |
| US6849263B2 (en) | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
| EP1161226B1 (en) | 1999-02-18 | 2004-05-26 | SuperGen, Inc. | Phosphocholine linked prodrug derivatives |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US6897034B2 (en) | 2001-06-11 | 2005-05-24 | Medarex, Inc. | CD10-activated prodrug compounds |
| US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| KR100822498B1 (ko) | 2002-02-22 | 2008-04-16 | 샤이어 엘엘씨 | 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물 |
| US20100092562A1 (en) | 2002-11-26 | 2010-04-15 | Hollenbeck R Gary | Sustained-release drug delivery compositions and methods |
| EP1782834A3 (en) | 2003-03-13 | 2007-08-01 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower abuse potential and extended duration of action |
| MXPA05009757A (es) | 2003-03-13 | 2005-12-05 | Controlled Chemicals Inc | Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida. |
| NZ544162A (en) | 2003-05-29 | 2008-09-26 | Shire Llc | Abuse resistant amphetamine compounds |
| NZ546226A (en) | 2003-09-30 | 2009-03-31 | Shire Llc | Oxycodone conjugates for prevention of overdose or abuse |
| EP1928881A2 (en) * | 2005-08-19 | 2008-06-11 | Pharmacofore, Inc. | Prodrugs of active agents |
| AU2006282799B2 (en) | 2005-08-26 | 2012-11-29 | Healthpartners Research & Education | Methods for treatment of headaches by administration of oxytocin |
| CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| PT1959948E (pt) | 2005-12-05 | 2012-09-12 | Xenoport Inc | Mesilato de pró-fármaco de levodopa, suas composições e suas utilizações |
| JP2009533443A (ja) | 2006-04-10 | 2009-09-17 | シャイア エルエルシー | 一置換及び二置換のオキシコドン化合物及び組成物 |
| AU2007238625A1 (en) | 2006-04-14 | 2007-10-25 | Shire Llc | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
| ES2456674T3 (es) | 2006-05-26 | 2014-04-23 | Signature Therapeutics, Inc. | Liberación controlada de opioides fenólicos |
| TWI401237B (zh) | 2006-07-24 | 2013-07-11 | ３-〔（１ｒ，２ｒ）-３-（二甲基氨基）-１-乙基-２-甲基丙基〕酚之製備 | |
| KR20090055616A (ko) | 2006-09-14 | 2009-06-02 | 스타파이어 시스템즈, 인크. | 고리형 유기실란의 합성 방법 |
| US20110105381A2 (en) | 2007-02-16 | 2011-05-05 | Pharmacofore, Inc. | Prodrugs of Peripheral Phenolic Opioid Antagonists |
| US20120142718A1 (en) | 2007-02-16 | 2012-06-07 | Jenkins Thomas E | N-17-Alkylated Prodrugs of Opioids |
| NZ586361A (en) | 2007-11-23 | 2012-09-28 | Gruenenthal Chemie | Tapentadol compositions |
| US9023860B2 (en) | 2007-11-26 | 2015-05-05 | Signature Therapeutics, Inc. | Pro-drugs for controlled release of biologically active compounds |
| AU2009214500B2 (en) | 2008-02-14 | 2014-10-23 | Alkermes, Inc. | Selective opioid compounds |
| US8802681B2 (en) | 2008-10-17 | 2014-08-12 | Signature Therapeutics, Inc. | Pharmaceutical compositions with attenuated release of phenolic opioids |
| US20100227921A1 (en) | 2009-03-03 | 2010-09-09 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
| KR20110134510A (ko) | 2009-04-02 | 2011-12-14 | 샤이어 엘엘씨 | 오피오이드의 신규한 디카르복실산 연결 아미노산 및 펩티드 프로드러그와 그 용도 |
| US20120270847A1 (en) * | 2009-07-17 | 2012-10-25 | Shire Llc | Novel carbamate amino acid and peptide prodrugs of opiates and uses thereof |
| JP2013503862A (ja) | 2009-09-08 | 2013-02-04 | シグネーチャー セラピューティクス，インク． | 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物 |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| ES2710617T3 (es) | 2010-04-21 | 2019-04-26 | Signature Therapeutics Inc | Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos |
| US20110262359A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| US9238020B2 (en) | 2010-04-21 | 2016-01-19 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug |
| US20110262360A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof |
| US20130079364A1 (en) | 2010-04-21 | 2013-03-28 | Signature Therapeutics, Inc. | Peripheral Opioid Agonists and Peripheral Opioid Antagonists |
| DE102010042013A1 (de) * | 2010-10-06 | 2012-04-12 | Robert Bosch Gmbh | Verfahren zur Einstellung einer Temperatur eines Sensorelements |
| US8497237B2 (en) | 2011-01-11 | 2013-07-30 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| ES2584634T3 (es) | 2011-01-11 | 2016-09-28 | Signature Therapeutics, Inc. | Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente |
| EP2683394B1 (en) | 2011-03-09 | 2021-01-06 | Signature Therapeutics, Inc. | Active agent prodrugs with heterocyclic linkers |
| US8685916B2 (en) * | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
-
2012
- 2012-03-08 EP EP12754373.4A patent/EP2683394B1/en active Active
- 2012-03-08 JP JP2013557882A patent/JP6148182B2/ja active Active
- 2012-03-08 BR BR112013022946A patent/BR112013022946A2/pt not_active Application Discontinuation
- 2012-03-08 AU AU2012225337A patent/AU2012225337B2/en active Active
- 2012-03-08 CA CA2827662A patent/CA2827662C/en active Active
- 2012-03-08 RU RU2013144368A patent/RU2608305C2/ru active
- 2012-03-08 WO PCT/US2012/028367 patent/WO2012122422A2/en not_active Ceased
- 2012-03-08 US US14/000,594 patent/US9139612B2/en active Active
- 2012-03-08 CN CN201280011870.8A patent/CN103813800B/zh active Active
-
2013
- 2013-09-01 IL IL228215A patent/IL228215B/en active IP Right Grant
-
2015
- 2015-08-13 US US14/825,880 patent/US20160002291A1/en not_active Abandoned